Author： Edwards I. Ralph
Publisher： Adis International
ISSN： 0114-5916
Source： Drug Safety, Vol.34, Iss.2, 2011-02, pp. : 93-96
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Prevention and Pharmacovigilance: What Should We Do, What Can We Do?
Drug Safety, Vol. 35, Iss. 2, 2012-02 ,pp. :
Access to resources
Recommend
What do Stakeholders Think about Pharmacovigilance?
Drug Safety, Vol. 33, Iss. 8, 2010-08 ,pp. :
Theoretical Arguments for the Discounting of Health Consequences: Where Do We Go from Here?
By Lazaro A.
PharmacoEconomics, Vol. 20, Iss. 14, 2002-01 ,pp. :
Neuropsychiatric Adverse Effects of Mefloquine: What Do We Know and What Should We Do?
By Nosten F.
CNS Drugs, Vol. 11, Iss. 1, 1999-01 ,pp. :
Healthcare: time for the public to do its bit?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 293, 2000-01 ,pp. :